Alexander Åstrand

Dr. Alexander Åstrand

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ØSØrjan Samuelsen
Ørjan Samuelsen
AÅAlexander Åstrand
Alexander Åstrand
CFChristopher Fröhlich
Christopher Fröhlich
AHAdam Heikal
Adam Heikal
SSSusann Skagseth
Susann Skagseth
PRPål Rongved
Pål Rongved
Carbapenem-resistant Gram-negative pathogens are a critical public health threat and there is an urgent need for new treatments. Carbapenemases (β-lactamases able to inactivate carbapenems) have been identified in both serine β-lactamase (SBL) and metallo β-lactamase (MBL) families. The recent introduction of SBL carbapenemase-inhibitors has provided alternative therapeutic options. Unfortunately, there are no approved inhibitors of MBL-mediated carbapenem-resistance and treatment options for infections caused by MBL-producing Gram-negatives are limited. Here, we present ZN148, a zinc-chelating MBL-inhibitor capable of restoring the bactericidal effect of meropenem and in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains (n=234). Moreover, ZN148 was able to potentiate the effect of meropenem against NDM-1-producing Klebsiella pneumoniae in a murine neutropenic peritonitis model. ZN148 showed no inhibition of the human zinc-containing enzyme glyoxylase II at 500 μM and no acute toxicity was observed in an in vivo mouse model with cumulative dosages up to 128 mg/kg. Biochemical analysis showed a time-dependent inhibition of MBLs by ZN148 and removal of zinc ions from the active site. Addition of exogenous zinc after ZN148 exposure only restored MBL activity by ∼30%, suggesting an irreversible mechanism of inhibition. Mass-spectrometry and molecular modelling indicated potential oxidation of the active site Cys221 residue. Overall, these results demonstrate the therapeutic potential of a ZN148-carbapenem combination against MBL-producing Gram-negative pathogens and that ZN148 is a highly promising MBL inhibitor, capable of operating in a functional space not presently filled by any clinically approved compound.

1 April 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
Elvar Örn ViktorssonElvar Örn Viktorsson
Elvar Örn Viktorsson
BGBendik Melling Grøthe
Bendik Melling Grøthe
RAReidun Aesoy
Reidun Aesoy
MSMisbah Sabir
Misbah Sabir
SSSimen Snellingen
Simen Snellingen
PRPål Rongved
Pål Rongved

27 November 2018 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
Alexander PöthigAlexander Pöthig
Alexander Pöthig
SASara Ahmed
Sara Ahmed
HWHanne Cecilie Winther-Larsen
Hanne Cecilie Winther-Larsen
SGShengyang Guan
Shengyang Guan
PAPhilipp J. Altmann
Philipp J. Altmann
AÅAlexander Åstrand
Alexander Åstrand
The biological activity of four pillarplex compounds featuring different metals and anions was investigated. The toxicity of the compounds against four bacterial strains [Bacillus subtilis (ATCC6633), Staphylococcus aureus (ATCC6538), Escherichia coli (UVI isolate), Pseudomonas aeruginosa], one fungus (Candida albicans), and a human cell line (HepG2) was determined. Additionally, a UV-Vis titration study of the pillarplexes was carried out to check for stability depending on pH- and chloride concentration changes and evaluate the applicability in physiological media. All compounds are bioactive: the silver compounds showed higher activity against bacteria and fungi, and the corresponding gold pillarplexes were less toxic against human cells.

8 March 2019 in MedChemComm
Verified
Journal Article
Closed access
PDF file
GKGeir Kildahl-Andersen
Geir Kildahl-Andersen
CSChristian Schnaars
Christian Schnaars
APAnthony Prandina
Anthony Prandina
SRSylvie Radix
Sylvie Radix
Marc Le BorgneMarc Le Borgne
Marc Le Borgne
AÅAlexander Åstrand
Alexander Åstrand
New MBL inhibitor renders resistant Gram negative bacteria susceptible to carbapenems.

18 December 2019 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Closed access
SESigvart Evjen
Sigvart Evjen
AÅAlexander Åstrand
Alexander Åstrand
MGMona Gaarder
Mona Gaarder
RPRagnhild E. Paulsen
Ragnhild E. Paulsen
AFAnne Fiksdahl
Anne Fiksdahl
HKHanna Katariina Knuutila
Hanna Katariina Knuutila

11 July 2024 in Carbohydrate Polymers
Verified
Journal Article
Closed access
MGMina Gravdahl
Mina Gravdahl
OAOlav Aarstad
Olav Aarstad
APAgnes B. Petersen
Agnes B. Petersen
SKStina G. Karlsen
Stina G. Karlsen
Ivan DonatiIvan Donati
Ivan Donati
GSGudmund Skjåk-Bræk
Gudmund Skjåk-Bræk